Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study

2001 Lipton, 2011, Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention study (P1342), Eur J Neurol, 18, 66 Ferrari, 2002, Triptans (serotonin 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials, Cephalalgia, 22, 633, 10.1046/j.1468-2982.2002.00404.x Tepper, 2003, Safety profile of the triptans, Expert Opin Drug Saf, 2, 123, 10.1517/14740338.2.2.123 MaasenVanDenBrink, 1998, Coronary side-effect potential of current and prospective antimigraine drugs, Circulation, 98, 25, 10.1161/01.CIR.98.1.25 Gallagher, 2003, Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment, Headache, 43, 36, 10.1046/j.1526-4610.2003.03006.x Neeb, 2010, 5-HT1F receptor agonists: a new treatment option for migraine attacks?, Neurotherapeutics, 7, 176, 10.1016/j.nurt.2010.03.003 Adham, 1997, Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog, Neuropharmacology, 36, 569, 10.1016/S0028-3908(97)00020-8 Nelson, 2010, Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan, Cephalalgia, 30, 1159, 10.1177/0333102410370873 Ferrari, 2010, Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan—a randomised proof-of-concept trial, Cephalalgia, 30, 1170, 10.1177/0333102410375512 Pilgrim, 2009, COL-144, an orally bioavailable selective 5-HT1F receptor agonist for acute migraine therapy, Cephalalgia, 29, 24 2004, International Classification of Headache Disorders: 2nd Edition, Cephalalgia, 24, 1 Liefaard, 2009, Prediction of therapeutically effective dose of COL-144 based on relationship between plasma concentrations and headache response (poster), Cephalalgia, 29, 24 Nam, 1987, A simple approximation for calculating sample sizes for detecting linear trend in proportions, Biometrics, 43, 701, 10.2307/2532006 Goldstein, 2001, Selective serotonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomized controlled trial, Lancet, 358, 1230, 10.1016/S0140-6736(01)06347-4 Bouchelet, 1996, Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels, Mol Pharmacol, 50, 219 Lucaites, 2005, [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain, Arch Pharmacol, 371, 178, 10.1007/s00210-005-1036-8 Dodick, 2004, Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms, Cephalalgia, 24, 417, 10.1111/j.1468-2982.2004.00694.x Loder, 2010, Triptan therapy in migraine, N Engl J Med, 363, 63, 10.1056/NEJMct0910887 Bruinvels, 1994, Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain, Neuropharmacology, 33, 367, 10.1016/0028-3908(94)90067-1 Ahn, 2009, Colocalization of 5-HT1F receptor and calcitonin gene-related peptide in rat vestibular nuclei, Neurosci Lett, 465, 151, 10.1016/j.neulet.2009.09.008 Ho, 2008, Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial, Lancet, 372, 2115, 10.1016/S0140-6736(08)61626-8 Diener, 2011, BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study, Cephalalgia, 31, 573, 10.1177/0333102410388435